TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00728455

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC 0070-0002-0349
Description: Dose level 1: (6 subjects active, 2 subjects placebo). Subjects administered NNC 0070-0002-0349 will receive a subcutaneous injection. Subjects in the first 3 dose groups will receive two injections: one of randomized treatment (drug or placebo) and placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC 0070-0002-0349
Description: Dose level 2: (6 subjects active, 2 subjects placebo). Subjects administered NNC 0070-0002-0349 will receive a subcutaneous injection. Subjects in the first 3 dose groups will receive two injections: one of randomized treatment (drug or placebo) and placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC 0070-0002-0349
Description: Dose level 3: (6 subjects active, 2 subjects placebo). Subjects administered NNC 0070-0002-0349 will receive a subcutaneous injection. Subjects in the first 3 dose groups will receive two injections: one of randomized treatment (drug or placebo) and placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC 0070-0002-0349
Description: Dose level 4 for s.c. injection (6 subjects active, 2 subjects placebo)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC 0070-0002-0349
Description: Dose level 5 for s.c. injection (6 subjects active, 2 subjects placebo)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Dose level 1: NNC 0070-0002-0349 placebo. Subjects administered placebo will receive a subcutaneous injection. Subjects in the first 3 dose groups will receive two injections: one of randomized treatment (drug or placebo) and placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Dose level 2: NNC 0070-0002-0349 placebo. Subjects administered placebo will receive a subcutaneous injection. Subjects in the first 3 dose groups will receive two injections: one of randomized treatment (drug or placebo) and placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Dose level 3: NNC 0070-0002-0349 placebo. Subjects administered placebo will receive a subcutaneous injection. Subjects in the first 3 dose groups will receive two injections: one of randomized treatment (drug or placebo) and placebo
Study: NCT04590625

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib Mesylate
Description: apatinib one course will last 21 days.Oral administration at a dose of 250 mg, qd

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib Mesylate
Description: apatinib one course will last 21 days.Oral administration at a dose of 250 mg, qd

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane
Description: abraxane one course will last 21 days.Intravenously guttae at a dose of 260 mg/m2,d1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane
Description: abraxane one course will last 21 days.Intravenously guttae at a dose of 260 mg/m2,d1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cis Platinum
Description: cis-platinum one course will last 21 days.cis-platinum introperitoneal injection at a dose of 75-100 mg/m2,d1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cis Platinum
Description: cis-platinum one course will last 21 days.cis-platinum introperitoneal injection at a dose of 75-100 mg/m2,d1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: carboplatin one course will last 21 days.carboplatin intravenous injection at a dose of AUC=5-6,d1
Study: NCT00728455

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Dose level 4: NNC 0070-0002-0349 placebo for s.c. injection
Study: NCT04647175

Intervention type: OTHER
Group type: OTHER
Intervention: Aronia
Description: Given twice daily for 8 weeks

Intervention type: OTHER
Group type: OTHER
Intervention: Aronia
Description: Given twice daily for 8 weeks

Intervention type: OTHER
Group type: OTHER
Intervention: Aronia
Description: Given twice daily for 8 weeks

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Given twice daily for 8 weeks

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Given twice daily for 8 weeks

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Given twice daily for 8 weeks
Study: NCT04311489

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ularitide
Description: Continuous intravenous infusion for 48 hours at a dose of 30 ng/kg/min. Depending on effect and/or side effects dose can be adjusted to 15 ng/kg/min or 45 ng/kg/min.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Continuous intravenous infusion for 48 hours at a bodyweight-adjusted infusion rate.
Study: NCT04590625

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: carboplatin one course will last 21 days.carboplatin intravenous injection at a dose of AUC=5-6,d1
Study: NCT02327702

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine
Description: emtricitabine were given to each patients at baseline till 48 weeks after delivery
Study: NCT04320433

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Oral glucose tolerance test
Description: Participants will ingest 75g anhydrous glucose dissolved in a volume of 200mL of water (NUTER.TEC GLUCOS, Subra, Toulouse, France).
Study: NCT02368288

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: entecavir
Description: in this group, entecavir will added, and patients will receive treatment of PEG-IFN a-2a combine with entecavir for 48 week.
Study: NCT01736722

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Visualase®
Description: The target tumor/lesion will undergo laser therapy using the MRI scan to plan the treatment and ensure proper placement of the laser within the tumor. An MRI (Magnetic Resonance Imaging) is a exam that creates pictures using magnetic rays instead of x-rays. The tumor(s) will then be heated by the laser in an attempt to eliminate their presence. The physician will be able to see and control the temperature of the laser.
Study: NCT04099797

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: C7R-GD2.CART cells (IV and ICV infusion)
Description: Dose levels administered are by IV infusion followed by ICV infusion.~Cycle 1: 10 million cells/m2 delivered IV with lymphodepletion.~Cycle 2 (and subsequent cycles):~Dose level 1: 2 million cells ICV with lymphodepletion. Dose level 2: 5 million cells ICV with lymphodepletion.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: C7R-GD2.CAR T cells (IV infusion)
Description: Dose levels administered are by IV infusion. For all cycles, the dose level is 10 million cells/m2 IV with lymphodepletion.
Study: NCT01702025

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Yellow corn meal in gel capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aminophylline
Description: National Drug Code (NDC) 0143-1020-01
Study: NCT02625636

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR438544
Description: Pharmaceutical form: solution~Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR438544
Description: Pharmaceutical form: solution~Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR438544
Description: Pharmaceutical form: solution~Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR438544
Description: Pharmaceutical form: solution~Route of administration: subcutaneous

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Pharmaceutical form: solution~Route of administration: subcutaneous

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: r-glucagon
Description: Pharmaceutical form: solution~Route of administration: subcutaneous
Study: NCT00296686

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranylcypromine
Description: standard dose:60 mg/d for a minimum of 8 weeks, a maximum of 17 weeks; high dose for non-remitters: up to 120 mg/day for a maximum of 9 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextroamphetamine
Description: up to 40 mg/day for 9 weeks, in combination with high dose of tranylcypromine for patients not remitting on the standard or high doses of tranylcypromine alone.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triiodothyronine
Description: For patients not remitting on higher dose of tranylcypromine plus dextroamphetamine: Up to 75 mg/day for 8 weeks(+/- dextroamphetamine) (max 8 weeks) in combination with highest does of tranylcypromine (up to 120mg/day).
Study: NCT01014013

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ertapenem sodium (MK0826)
Description: a single daily dose of ertapenem sodium 1.0g IV infused over 30 minutes, for 7-14 days (patients may be switched to oral ciprofloxacin after 3 doses of IV therapy if needed)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: ceftriaxone sodium
Description: a single daily dose of ceftriaxone 2.0g IV infused over 30 minutes, for 7-14 days (patients may be switched to oral ciprofloxacin after 3 doses of IV therapy)
Study: NCT01702025

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methazolamide
Description: NDC 0781-1072-01
Study: NCT04647175

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Given twice daily for 8 weeks

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Given twice daily for 8 weeks

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Given twice daily for 8 weeks
Study: NCT04209426

Intervention type: DEVICE
Intervention: THA with SYMBOL CUP DMR HA

Intervention type: DEVICE
Intervention: THA with SYMBOL CUP DM CEM
Study: NCT02396524

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hockey FIT Program
Description: Active phase: a) Classroom-based education on successful weight management strategies and instruction on behaviour change techniques/dietary interventions; promote peer and other forms of social support; and b) Physical activity sessions in aerobic/strength/flexibility exercises. Maintenance phase: Participants independently set new lifestyle prescriptions and goals and track their exercise, physical activity, and healthy eating with the support of a suite of free-of-charge health technology support tools
Study: NCT00931866

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac Sodium
Description: Topical diclofenac patch applied once daily to area of pain

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo Patch
Description: Matching placebo patch, containing identical constituents to the active comparator except for diclofenac sodium; applied once daily
Study: NCT00728455

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Dose level 5: NNC 0070-0002-0349 placebo for s.c. injection
Study: NCT01059461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cerebrolysin®
Description: injection of cerebrolysin® 0.1ml/kg IM twice weekly for 10 injections after discharge from NICU (postneonatal)
Study: NCT02729298

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TP-0903
Description: Novel oral inhibitor that targets AXL kinase and reverses the mesenchymal phenotype associated with advanced cancers

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TP-0903
Description: Novel oral inhibitor that targets AXL kinase and reverses the mesenchymal phenotype associated with advanced cancers

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TP-0903
Description: Novel oral inhibitor that targets AXL kinase and reverses the mesenchymal phenotype associated with advanced cancers
Study: NCT02920866

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Functional Strength Integration (FSI)
Description: FSI intervention involves strengthening of the hip musculature combined with focused techniques emphasizing early initiation of hip muscle recruitment to stabilize the pelvis, integrating strength and movement pattern training to maximize functional recovery. The FSI program consists of therapeutic exercise in 3 domains: pelvic stability (PST) training, functional training (FT), and strength training (ST). PST includes early surgical-limb weight bearing and core muscle strengthening, progressively increasing in difficulty based on performance benchmarks and therapist monitoring. FT focuses on gait and stair climb exercise, progressing to higher level agility training. ST includes progressive, resistance exercise to improve lower extremity muscle strength. The ST exercises include use of weighted pulleys/weight-training machines. Therapists will determine an 8-rep max for muscle groups and weight will be increased by 10% every 2 weeks to maximize hypertrophy and strength gains.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Group (CON)
Description: Observed practice patterns from previous investigations and discussion with physical therapists indicate that patients receive rehabilitation services during the 2-3 day hospital stay after THA, but not routinely after hospital discharge. Yet, to control for attention and volume of rehabilitation for the FSI group, patients in the control group will attend outpatient physical therapy for 14 visits (40 minute sessions) over 8 weeks. This control program will mimic the typical postoperative experience for patients in our community, in which patients independently manage their activity. This program will focus on patient education, functional ADL training, and therapeutic exercise. However, the activities in the exercise domain will be limited to low load exercise such as isometric muscle exercise, range of motion (ROM), and flexibility activities. These activities are specifically designed to mirror usual care activity.
Study: NCT02900508

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exergaming training

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical therapy intervention
Study: NCT02010671

Intervention type: OTHER
Intervention: Survey
Description: Survey
Study: NCT01702025

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aminophylline+Methazolamide
Description: NDC 0143-1020-01 and NDC 0781-1072-01
Study: NCT00704938

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aldesleukin
Description: Intravenous (IV) aldesleukin 720,000 IU/kg every 8 hours for a maximum of 15 doses.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aldesleukin
Description: Intravenous (IV) aldesleukin 720,000 IU/kg every 8 hours for a maximum of 15 doses.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-p53 T-cell receptor-transduced peripheral blood lymphocytes
Description: Intravenous (IV) anti-p53 TCR transduced PBL will be administered at a a dose of 1 x 10\^8 cells to 5 x 10\^10 cells.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-p53 T-cell receptor-transduced peripheral blood lymphocytes
Description: Intravenous (IV) anti-p53 TCR transduced PBL will be administered at a a dose of 1 x 10\^8 cells to 5 x 10\^10 cells.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous dendritic cell-adenovirus p53 vaccine
Description: Ad-p53 DC vaccine, up to 2 x 10\^8 ad-p53 DCs per dose will be administered subcutaneously, divided into 4 injections, one into each of the 4 extremities. Ad-p53 DCs will be administered subcutaneously on day 7 (± 2 days), day 14 (between day 14 and day 18), and day 28 (between day 25 and day 42) post T cell infusion.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous dendritic cell-adenovirus p53 vaccine
Description: Ad-p53 DC vaccine, up to 2 x 10\^8 ad-p53 DCs per dose will be administered subcutaneously, divided into 4 injections, one into each of the 4 extremities. Ad-p53 DCs will be administered subcutaneously on day 7 (± 2 days), day 14 (between day 14 and day 18), and day 28 (between day 25 and day 42) post T cell infusion.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: subcutaneously at a dose of 5 mcg/kg/day (not to exceed 300 mcg/day).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: subcutaneously at a dose of 5 mcg/kg/day (not to exceed 300 mcg/day).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 60mg/kg/day (Days-7,-6)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 60mg/kg/day (Days-7,-6)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: 25mg/m\^2 (Days -5, -4, -3, -2, and -1)
Study: NCT02729298

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TP-0903
Description: Novel oral inhibitor that targets AXL kinase and reverses the mesenchymal phenotype associated with advanced cancers

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TP-0903
Description: Novel oral inhibitor that targets AXL kinase and reverses the mesenchymal phenotype associated with advanced cancers
Study: NCT04021888

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Education of patients and their caregivers, deep breathing exercise, aerobic exercise and resistance training with elastic bands

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Education of patients and their caregivers, deep breathing exercise, aerobic exercise and resistance training with elastic bands
Study: NCT02492373

Intervention type: DRUG
Group type: OTHER
Intervention: topical 0.05% Clobetasol propionate ointment
Description: Apply only on the treated area twice a day as mentions

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: topical 0.05% Clobetasol propionate ointment
Description: Apply only on the treated area twice a day as mentions

Intervention type: DEVICE
Group type: OTHER
Intervention: Q switched Nd:YAG laser 532 nm
Description: Treatment of facial lentigines. The energy using depends on the endpoint of immediate whitening of the lesions.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Q switched Nd:YAG laser 532 nm
Description: Treatment of facial lentigines. The energy using depends on the endpoint of immediate whitening of the lesions.
Study: NCT00704938

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: 25mg/m\^2 (Days -5, -4, -3, -2, and -1)
Study: NCT03410563

Intervention type: BEHAVIORAL
Intervention: Auditory inputs
Description: Three different auditory inputs
Study: NCT00659932

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Immediate Cognitive behavioural therapy (CBT)
Description: The Dealing with Anxiety CBT Group Program comprises 7 group sessions: an initial five hour session followed by 6 three hour sessions over a three month period

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Delayed CBT
Description: Commencement of the CBT Group Program is delayed 3 months
Study: NCT01293825

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ziprasidone
Description: Patients will identify which psychotropic they currently receive that causes the most weight-gain concern. For individuals on multiple drugs, one drug must be identified as the offending agent. Study psychiatrist will switch the offending agent to ziprasidone. Participants will be switched to ziprasidone per package insert. Patients will be maintained on ziprasidone for 12 weeks (active part of study). After the active part of the study they will return to the care of their normal clinical provider who will determine whether they will continue on ziprasidone.
Study: NCT01209351

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study: NCT00616850

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous femoral catheter block
Description: A constant infusion of ropivacaine 0.2% without epinephrine will be given to each subject via continuous femoral catheter in Group A.
Study: NCT01209351

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: teduglutide
Description: teduglutide 4 mg
Study: NCT01484535

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Ankle Aspiration
Description: Ankle aspiration will be performed through either a standard anterolateral or anteromedial approach, depending on the conditions of the soft tissue. The anterolateral approach will be the preferred method due to the higher reproducibility of intra-articular needle placement. The anteromedial approach will be reserved for patients whose soft tissues over the anterolateral portal are compromised. Sterile preparation of the limb will be achieved with the use of chlorhexidine or Betadine. An 18 gauge needle will be introduced into the ankle joint and a syringe will be used to aspirate the ankle until no more hemarthrosis is able to be removed. The amount of hemarthrosis aspirated will be recorded. Following the procedure, care will continue as per standard of care.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Ankle aspiration Standard Anterolateral
Description: Placebo ankle aspiration will be performed through a standard anterolateral. Sterile preparation of the limb will be achieved with the use of chlorhexidine or Betadine. An 18-gauge needle will be introduced into the skin. The needle will be held in the skin for 5-10 seconds in an effort to simulate the pain and time-lag experienced with aspiration. The needle will not pass the fascia or ankle joint capsule. Following the procedure, care will continue as per standard of care.
Study: NCT00616850

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Lidocaine 1.33mg/kg/hr continuous IV infusion following induction of general anesthesia to 24 hours postoperatively.
Study: NCT04068246

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: 1000 mg of Metformin table taken orally daily plus Methotrexate 7.5 mg weekly

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet plus plus Methotrexate 7.5 mg weekly
Study: NCT03035604

Intervention type: OTHER
Intervention: Comprehensive Geriatric Assessment
Description: Undergo nutritional geriatric assessment
Study: NCT04724863

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Angioscan
Description: The study procedure foresees to take images during a deep breath as well as deep exhalation. This second measurement does not require the administration of an additional amount of contrast material. However, the exposure time to ionising radiation is doubled. The examination uses helical acquisition in fast mode. The duration of the helix is of the order of 2 seconds in the inspiration phase, then there is a delay of 5 seconds of machine time (half-turn) and again 2 seconds of exposure in the expiration phase, i.e. 4 seconds of actual exposure to ionizing radiation, the time of image taking and 9 seconds the total time of the examination.